Parallel Advisors LLC reduced its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 13.1% in the first quarter, HoldingsChannel reports. The firm owned 629 shares of the medical equipment provider’s stock after selling 95 shares during the period. Parallel Advisors LLC’s holdings in Zimmer Biomet were worth $80,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the business. Moors & Cabot Inc. grew its stake in Zimmer Biomet by 91.6% in the first quarter. Moors & Cabot Inc. now owns 5,596 shares of the medical equipment provider’s stock valued at $716,000 after acquiring an additional 2,675 shares during the period. Alps Advisors Inc. grew its stake in Zimmer Biomet by 88.3% in the first quarter. Alps Advisors Inc. now owns 6,671 shares of the medical equipment provider’s stock valued at $852,000 after acquiring an additional 3,128 shares during the period. Menta Capital LLC acquired a new stake in Zimmer Biomet in the first quarter valued at approximately $695,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in Zimmer Biomet by 45.8% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 3,852 shares of the medical equipment provider’s stock valued at $492,000 after acquiring an additional 1,210 shares during the period. Finally, Public Employees Retirement Association of Colorado grew its stake in Zimmer Biomet by 4.9% in the first quarter. Public Employees Retirement Association of Colorado now owns 38,042 shares of the medical equipment provider’s stock valued at $4,858,000 after acquiring an additional 1,775 shares during the period. Institutional investors and hedge funds own 89.64% of the company’s stock.
ZBH stock opened at $118.66 on Tuesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.97 and a current ratio of 2.00. Zimmer Biomet Holdings Inc has a 1-year low of $96.99 and a 1-year high of $134.55. The firm has a market capitalization of $24.97 billion, a price-to-earnings ratio of 15.53, a price-to-earnings-growth ratio of 2.24 and a beta of 1.19.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, March 28th. This represents a $0.96 annualized dividend and a yield of 0.81%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.
In other Zimmer Biomet news, Director Syed A. Jafry acquired 1,925 shares of the business’s stock in a transaction on Friday, March 1st. The shares were acquired at an average price of $125.52 per share, with a total value of $241,626.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arthur J. Higgins acquired 500 shares of the business’s stock in a transaction on Friday, February 15th. The stock was acquired at an average cost of $123.28 per share, for a total transaction of $61,640.00. Following the transaction, the director now owns 2,400 shares of the company’s stock, valued at approximately $295,872. The disclosure for this purchase can be found here. In the last three months, insiders acquired 4,425 shares of company stock worth $550,506. Insiders own 0.72% of the company’s stock.
A number of brokerages have commented on ZBH. Cantor Fitzgerald set a $135.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Friday, April 26th. Barclays set a $113.00 target price on Zimmer Biomet and gave the company a “sell” rating in a research report on Tuesday, February 5th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Saturday, February 2nd. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $130.19.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.